PIK3CB and neoplasm: Histopathology analysis of representative tumors at assay termination showed that, at difference from controls, tumor vestiges from E-cad-low PIK3CB shRNA-treated UMUC-9 cells were composed essentially of dying or dead cells; TUNEL analysis of these samples confirmed apoptosis in PIK3CB shRNA-treated tumors from E-cad-low UMUC-9 cells (Figure 6b, 6c).